My point is that I view this stock as much more than a 250
My point is that I view this stock as much more than a 250 share investment and hope it pans out to an $8750 return.
That is like the owners of Secretariat hoping that one day they would make $10,000 off his winnings just prior to the Triple Crown. They had the vision to see that they had perhaps the greatest racehorse of all time.
I see IPIX as a Secretariat of the biotech industry and as such I expect the same type of returns that the Penny family received from Secretariat.
Guess it all boils down to vision. As stated in "Patriot Games" if "aim small, miss small" is your cup of tea invest about $150 in IPIX and hope for $8750. If your vision is to aim big and reach out to grasp the golden ring, then you bet large and expect massive returns. I believe the trial data to date and the interest from 20 BP CDAs makes a very large investment in IPIX a prudent investment, especially at this stage of the game. Note: A large investment is subjective for each investor's financial situation and if all they can afford is $250 or so, then I applaud them for taking the risk.
$35 a share is somewhere around a buyout of $8B for IPIX. Hell, Prurisol for psoriasis alone, even with P2b clinical data being only slightly better than 200 dosage arm, IMO should result in revenues of $50B or so over the life of the Prurisol patent.
So when I see people valuing IPIX like a one drug, one indication, at a pre-clinical or pre-Phase I trial stage, with maybe one BP showing interest in them and they needing funds immediately to prevent bankruptcy, I shudder.
If one can't see the true value of IPIX, then IMO they don't deserve to be in this stock and make money from its success.
11
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Corporate Deals Under the Microscope: What's at Stake? The headlines are shouting: ADT, Instacart, and Ultralife are all embroiled in merger activities that might not exactly be what shareholders signed up for. On the surface, you've got big names like DoorDash stepping up to snag some of these firms, but the question here is whether the deals are truly fair—or if...
Continue Reading
Candy Challenges: Embracing Sweet Joys Responsibly Think you're done with Halloween? Nope. Welcome to the endless candy seasons when every festivity seems like an outlet for sugar overload—with parents caught between letting kids enjoy and guarding their teeth. Now, with Spry's recent push around xylitol, there's an option that might just mean an easier peace between...
Continue Reading
Hudsonville's New Chapter: Enter CJ Ellens When a firm as storied as Hudsonville Ice Cream elects a new captain at the helm, folks sit up and take notice. CJ Ellens, already well-embedded in the fabric of Hudsonville, is set to steer the ship starting January 1, 2027. This isn't just a revolving door of C-suites, but more like a passing of the torch to someone bred in the...
Continue Reading
The Landmark Year in Fine Dining Spago Shanghai just blew out its first candle, folks, and what a year it's been. From its lofty perch in The St. Regis on the Bund, this hub of culinary magic has carved out a name with accolades aplenty, a hard feat among the many fine-dining heavyweights dotting the Shanghai skyline. A Transplant of California Flavors You take a seat...
Continue Reading
The Strategy Behind Atlas Power's Expansion Atlas Power Partners, no stranger to sizzling ambitions, has galvanized its portfolio by roping in Boyland Electric. This latest maneuver unfolds as Atlas hustles to become the go-to network for residential generator services. It’s a clear bet on 'quality over flair'—an ethos echoed by their CEO, David Fischer, who champions...
Continue Reading
Millrose's Uneasy Alliance With Trouble When it rains, it pours, doesn't it? Millrose Properties, Inc.—your friendly neighborhood real estate developer—has got itself caught in the crosshairs of a securities fraud lawsuit. Investors who've been cozying up to Millrose's stock from February 7, 2025, all the way to October 2, 2026, find themselves at the mercy of...
Continue Reading
Deere & Company Expands Leadership with Boland Out of the blue, Deer & Company (NYSE: DE) decided to shake things up by adding Julie Boland, the former U.S. honcho at Ernst & Young LLP, to their board. Now, when Deere gets a leader with her pedigree, there’s more than a whiff of strategy at play. Let’s unpack why Deere's pulling the trigger on this boardroom shift....
Continue Reading
Brightstar Aims for the Jackpot at WLS 2026 Don't kid yourself—this isn't your granddad's corner-store lottery ticket. Brightstar Lottery PLC, trading as NYSE: BRSL, is pushing the envelope at the World Lottery Summit 2026 in Sydney, flaunting a roster of high-tech and savvy solutions to meet changing player expectations. It's a collision of tradition and tech, all...
Continue Reading
A Rising Star in the Banking World You don't see a lot of folks these days making waves in the banking sector quite like Kirk Goehring has. And it's a decent feat, earning a nod from the American Bankers Association (ABA) as one of their 2026 Emerging Leader Awards recipients. For those of you wondering if this is just another hollow accolade, think again. The ABA doesn't...
Continue Reading
Florida Properties: The Buried Risk in Flood Zones If you’re dreaming of palm trees and sandy beaches, don't let flood zones turn that dream into a nightmare. It’s not all sunshine and rainbows when it comes to buying real estate in Florida, as it turns out—flood zones are lurking, and the devil's in the details. Understanding FEMA Flood Maps First off, these FEMA...
Continue Reading
Top 5 Most Recently Viewed Articles
Akoya Biosciences Joins Force in Cancer Research Initiative Akoya Biosciences, Inc. (NASDAQ: AKYA), often recognized as The Spatial Biology Company, has officially announced its involvement in the MANIFEST program, a substantial cancer research initiative. The program, backed by the UK Office of Life Sciences and the Medical Research Council, is dedicated to enhancing the...
Continue Reading
Heron Therapeutics Welcomes Michael Kaseta to Its Board Heron Therapeutics, Inc. (NASDAQ: HRTX), a forward-thinking biotechnology company, recently made a significant announcement regarding its leadership. The organization is pleased to share the addition of Michael Kaseta to its Board of Directors. His vast experience in corporate finance and business strategy is set to...
Continue Reading
Bardstown Bourbon Company’s Distillery Expansion Journey In 2014, the Bardstown Bourbon Company embarked on a journey to establish a remarkable distillery on 100 acres of pristine farmland. Fast forward ten years, this ambitious project has culminated in the completion of the most significant expansion to date for the company. This enhancement elevates the...
Continue Reading
PDF Solutions Stock Overview In today's fluctuating market, PDF Solutions, Inc. (NASDAQ: PDFS) is making headlines as its stock recently dipped to a 52-week low of $27.68. This drop raises several questions about the company's future, especially considering the prevailing trends affecting technology stocks. Understanding the reasons behind this dip is crucial for...
Continue Reading
Understanding the Class Action Lawsuit Against CTO Realty Growth Inc. In recent news, CTO Realty Growth, Inc. is at the center of an important class action lawsuit that involves potential compensation for investors. This lawsuit emphasizes the significance of the actions taken by the company's leadership during the class period marked between certain dates. If you've...
Continue Reading